NCT05210114 is a NA clinical trial of Skin Hydration Sensor in Sickle Cell Disease, sponsored by Enrico Novelli.

Who is sponsoring NCT05210114?

NCT05210114 is sponsored by Enrico Novelli.

What drugs are being tested in NCT05210114?

Interventions in NCT05210114: Skin Hydration Sensor.

What condition does NCT05210114 study?

NCT05210114 studies Sickle Cell Disease.

Is NCT05210114 still recruiting?

NCT05210114 is currently recruiting now. Last updated 12 November 2025.

Last reviewed 2025-11-12 · How we verify

NCT05210114

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cutaneous Hydration Assessment in SCD

Recruiting now NA Last updated 12 November 2025

What this trial tests

NA trial testing Skin Hydration Sensor in Sickle Cell Disease in 30 participants. Currently enrolling.

Timeline

21 January 2022

Primary endpoint
31 December 2026

31 December 2027

Quick facts

Lead sponsor	Enrico Novelli
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	30
Start date	21 January 2022
Primary completion	31 December 2026
Estimated completion	31 December 2027
Sites	1 location across United States

Drugs / interventions tested

Skin Hydration Sensor

Conditions studied

Sickle Cell Disease — all drugs for Sickle Cell Disease →

Sponsor

Enrico Novelli — full company profile →

Who can join

12 and older, any sex, with Sickle Cell Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will validate the diagnostic accuracy of a cutaneous hydration sensor. This sensor will also be evaluated for its feasibility as a point-of-care device for the assessment of hydration status and its potential to guide hydration therapy in patients with sickle cell disease (SCD).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Sickle Cell Disease

Currently open trials in the same condition.

NCT07369024 — Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults · Phase 2 · recruiting
NCT06016634 — Alendronate for Osteonecrosis in Adults With Sickle Cell Disease · Phase 2 · recruiting
NCT06260891 — Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial · Phase 2 · recruiting
NCT07222475 — Writing Relaxing Beats in Adolescents Who Have Sickle Cell Disease · NA · recruiting
NCT07224360 — Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD) · Phase 2 · recruiting

Other Enrico Novelli trials

Trials by the same sponsor.

NCT04925492 — PET Imaging of Vaso-Occlusive Crisis (VOC) in SCD · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05210114 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Enrico Novelli
Last refreshed: 12 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05210114.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing